Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseскороОткрытый API экосистемы
Статья

Nanomedicine and nutraceutical-based nanocarriers for specific delivery to cancer stem cells: targeted drug delivery at the STEM frontier

Enas DaoudFaculty of Pharmacy, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, JordanWaleed K. AbdulsahibDepartment of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq. [email protected]Sajida Hussein IsmaelCollege of Pharmacy, Al-Turath University, Baghdad, IraqR. RoopashreeDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, IndiaSubhashree RayDepartment of Biochemistry, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, Odisha, 751003, IndiaJayshree NelloreDepartment of Biotechnology, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, IndiaGunjan MukherjeeUniversity Institute of Biotechnology, Chandigarh University, Mohali, Punjab, IndiaAshish Singh ChauhanUttaranchal Institute of Pharmaceutical Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, IndiaMohigul KholiyevaDepartment of Medicine, Termez University of Economics and Service, Termez, Uzbekistan
Discover Oncologyjournal2025en
ABI

Аннотация

Cancer stem cells (CSCs) represent a highly plastic and therapy-resistant subpopulation within tumors, driving tumor initiation, progression, metastasis, and relapse. Their ability to evade conventional treatments necessitates novel, highly specific therapeutic strategies. Nanomedicine offers a transformative approach to overcome the limitations of traditional therapies by enabling targeted and controlled drug delivery. This review explores the synergistic potential of combining advanced nanocarriers with potent nutraceuticals, emphasizing their capacity to modulate critical CSC signaling pathways and overcome inherent bioavailability challenges. The review first outlines the unique biological characteristics of CSCs that make them elusive therapeutic targets. It then delineates the principles of nanomedicine for precise drug delivery and details the anti-CSC mechanisms of various promising nutraceuticals. Furthermore, it examines innovative nanocarrier-based strategies designed for specific CSC targeting, such as curcumin-loaded solid lipid nanoparticles and resveratrol-hydrogels, presenting compelling preclinical evidence. Finally, the report addresses the significant translational challenges that must be overcome for these advanced therapies to reach clinical fruition, underscoring the transformative potential of emerging technologies, such as biomimetics, microfluidics, and artificial intelligence, in advancing targeted CSC therapies at the “STEM Frontier” of oncology.

Перевод пока недоступен

Темы

Идентификаторы

Цитирования и источники

Показатели — AkademScholar · Скоро